Not study the phase II metabolism. A chromatogram displaying the mass traces of all the above-mentioned metabolites and signals in this study is provided in Figure 4. As a result of the higher abundancy of your dihydroxylated metabolite MA9, this metabolite is suggested as a appropriate biomarker for urine screenings. Nevertheless, as a consequence of limitations of in vitro models, verification in vivo byMetabolites 2021, 11,13 ofana-lysis of optimistic human urine samples is necessary. The proposed metabolic nNOS Inhibitor MedChemExpress pathway is presented in Figure five. Fragmentation in the parent compound ADAMANTYL-THPINACA resulted in only one fragment at m/z 135.1168. Variation in the collision energies did not result in additional diagnostic ions for the parent compound (data not shown). Further diagnostic fragments had been detected for the metabolites of ADAMANTYL-THPINACA. Metabolites 2021, 11, x FOR PEER Overview 14 of 26 The respective MS2 spectra of ADAMANTYL-THPINACA, incorporating the 3 most abundant metabolites with their suggested fragments, are shown in Figure six.Figure four. Chromatogram displaying the the mass traces with the detected metabolites (and of ADAMANTYL-THPINACA four. Chromatogram showing mass traces on the detected metabolites (and artefacts) artefacts) of ADAMANTYLTHPINACA after two h of incubation. The traces are normalized a maximum a maximum at 12 of (MA9). just after 2 h of incubation. The traces are normalized globally, withglobally, withat 12 from the base peakthe base peak (MA9).Metabolites 2021, 11, 470 Metabolites 2021, 11, x FOR PEER REVIEW14 of 25 15 ofOMAOOONOHNONMANHN NorNHNN NOADAMANTYL-THPINACANHOH OHOONHOHOHOOOOHNOOHN NNMANHONMANHONMA1 MANHOOHOHOH OHOOOOOHNON NMA5 MANHON NMANHN NMANHOHN NMANH ONMANHOOOOH OHOH OH OHOHOHOH OHON NMANHOOH OFigure five. Proposed metabolic pathway of ADAMANTYL-THPINACA. Figure five. Proposed metabolic pathway of ADAMANTYL-THPINACA.Metabolites 2021, 11, x FOR PEER Assessment Metabolites 2021, 11,16 of 26 15 of135.ADAMANTYL-THPINACA394.N NORelative Abundance80 60ONH135.20 0 150 200 250 m/z one NPY Y5 receptor Antagonist Purity & Documentation hundred 300 350 400 426.OMARelative AbundanceN60 40 20 0 150 200 250 m/z 300 350149.0960 167.1064 131.N243.243.ONHOH OH167.1067 149.0961 (-H2O) 131.0855 (2 x -H2O)100 Relative AbundanceMA151.410.ON N60 40 20 0 150 200 250 m/zO133.NHOH300 350424.O151.1117 133.1012 (-H 2O)MARelative AbundanceN60 40 20 0 50 one hundred 150 200 250 m/z 300 350 400 four 149.0959 131.0854 1 167.1063 241.0962 259.N425.241.1044 259.ONHOH OH167.1067 149.0961 (-H2O) 131.0855 (two x -H2O)Figure six. MS2 spectra of ADAMANTYL-THPINACA and its 3 most abundant metabolites. The proposed fragments Figure six. MS2 spectra of ADAMANTYL-THPINACA and its three most abundant metabolites. The proposed fragments top towards the respective signals are shown on the proper. top for the respective signals are shown around the suitable.Table three. Summary of all detected metabolites, and observed artefacts thereof, of ADAMANTY-THPINACA (listed in the order in the observed retention times). Shown will be the recommended biotransformations, chemical formulas, calculated [M + H] on the parent ions and the corresponding item ions, too as retention instances, location soon after two h of incubation, and rank. ID MA1 Biotransformation di-hydroxylation at adamantyl, mono-hydroxylation at 4methyl-tetrahydropyran Formula C24H31N3O5 [M + H]+ Product ions (m/z) 442.2336 424.2221 259.1077 167.1067 149.0961 131.0855 442.2336 424.2221 259.1077 167.1067 149.0961 131.0855 424.2231 259.1077 241.1044 167.1067 149.0961 131.0855 424.2231 Mass error (ppm) 1.4 Rt (min) 0.87 Location (n =.